In brief: Insulin by inhaler: new option for diabetes treatment
In brief
For the first time since the introduction of insulin more than 80 years ago, a non-injectable way of taking the hormone will be available. Exubera, a fast-acting inhaled insulin, was approved by the FDA in January 2006 and should be on the market by mid-year. Pfizer, which developed the drug and inhaler with Sanofi-Aventis and Nektar Therapeutics, says that a needle-free option will benefit people with diabetes who need insulin but delay treatment because they fear the injections.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
